AAV vectors: is clinical success on the horizon?
- 1 January 2000
- journal article
- review article
- Published by Springer Nature in Gene Therapy
- Vol. 7 (1) , 24-30
- https://doi.org/10.1038/sj.gt.3301109
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 54 references indexed in Scilit:
- Transduction and Utility of the Granulocyte-Macrophage Colony-Stimulating Factor Gene into Monocytes and Dendritic Cells by Adeno-Associated VirusJournal of Interferon & Cytokine Research, 2000
- Progress in Adeno-Associated Virus Type 2 Vector Production: Promises and Prospects for Clinical UseHuman Gene Therapy, 1999
- Persistent expression of canine factor IX in hemophilia B caninesGene Therapy, 1999
- Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2Gene Therapy, 1999
- High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and CapGene Therapy, 1999
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yieldGene Therapy, 1999
- High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle VirusHuman Gene Therapy, 1998
- Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primatesGene Therapy, 1998
- In vitro packaging of an infectious recombinant adeno-associated virus 2Gene Therapy, 1997
- NIDDK Workshop on AAV Vectors: Gene Transfer into Quiescent CellsHuman Gene Therapy, 1996